Leufolic

Folinic Acid, the active ingredient in Leufolic, is a folate derivative presented as a solution for intramuscular and intravenous use. It is employed as rescue therapy for methotrexate toxicity, as an adjunct in cancer chemotherapy regimens, and for the treatment of folate deficiency in patients requiring rapid restoration of intracellular folate pools.

GNH USA supplies Leufolic as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, and pharmacies worldwide, providing reliable sourcing for clinical use.

Leufolic is used in clinical settings that involve folate pathway disruption or deficiency, supporting patients across several therapeutic areas.

- Methotrexate toxicity: provides rescue therapy to restore folate levels and reduce toxic effects. - Cancer chemotherapy: serves as an adjunct to enhance efficacy and mitigate folate‑depleting effects of certain chemotherapeutic agents. - Folate deficiency: treats patients with inadequate folate status, supporting DNA synthesis and repair processes.

Leufolic may be associated with a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Nausea: mild to moderate discomfort in the stomach. - Vomiting: occasional episodes following administration. - Diarrhea: loose stools that resolve with continued therapy. - Rash: mild skin erythema or itching. - Fever: low‑grade temperature elevation. - Headache: transient mild headache.

Serious or Rare Side Effects: - Anaphylactic reaction: rare but severe allergic response requiring immediate medical attention. - Severe hypotension: sudden drop in blood pressure, potentially life‑threatening. - Acute renal impairment: rare kidney function decline. - Stevens‑Johnson syndrome: severe skin and mucous membrane reaction. - Seizures: uncommon neurologic event. - Hemolysis: rare breakdown of red blood cells.

When using Leufolic, clinicians should consider several safety measures to minimize risk.

- Renal function: assess and adjust dosing in patients with severe renal impairment. - Pregnancy: use only if the potential benefit justifies the potential risk to the fetus. - Breastfeeding: evaluate risk versus benefit before administration to nursing mothers. - Allergy: avoid in individuals with known hypersensitivity to folinic acid or its excipients. - Compatibility: verify diluent compatibility before intravenous infusion. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Folinic Acid can interact with other medications, influencing efficacy or safety.

Major Interactions (Avoid): - Concurrent methotrexate administration without appropriate timing: may diminish methotrexate's therapeutic effect. - Antifolate agents (e.g., pemetrexed): folinic acid can antagonize their anticancer activity.

Moderate Interactions (Monitor Closely): - Cytarabine: potential increased hematologic toxicity; monitor blood counts. - Carboplatin: enhanced nephrotoxicity risk; assess renal function. - High‑dose vitamin B12 supplementation: may alter folate metabolism; observe for clinical changes.